BIAF — BioAffinity Technologies Share Price
0.000.00%
Last trade - 00:00- $8.18m
- $8.11m
- $9.36m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.15 | ||
| Price to Tang. Book | 19.38 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.87 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -262.64% | ||
| Return on Equity | -242.44% | ||
| Operating Margin | -95.64% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 0 | 2.53 | 9.36 | 6.05 | 7.25 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
bioAffinity Technologies, Inc. is a biotechnology company focused on the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatments. It develops noninvasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis developed by machine learning, a form of artificial intelligence (AI). The Company’s product, CyPath Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of the Company. CyPath Lung uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- March 26th, 2014
- Public Since
- August 26th, 2022
- No. of Shareholders
- 92
- No. of Employees
- 57
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 18,248,623
- Address
- 3300 Nacogdoches Road, Suite 216, SAN ANTONIO, 78217
- Web
- https://bioaffinitytech.com/
- Phone
- +1 2106985334
- Contact
- Julie Overton
- Auditors
- WithumSmith Brown PC
Upcoming Events for BIAF
Q1 2025 bioAffinity Technologies Inc Earnings Release
Q1 2025 bioAffinity Technologies Inc Earnings Release
bioAffinity Technologies Inc Annual Shareholders Meeting
bioAffinity Technologies Inc Annual Shareholders Meeting
bioAffinity Technologies Inc Annual Shareholders Meeting
bioAffinity Technologies Inc Annual Shareholders Meeting
bioAffinity Technologies Inc Annual Shareholders Meeting
bioAffinity Technologies Inc Annual Shareholders Meeting
Q2 2025 bioAffinity Technologies Inc Earnings Release
Q2 2025 bioAffinity Technologies Inc Earnings Release
Q2 2025 bioAffinity Technologies Inc Earnings Release
Similar to BIAF
Accelerate Diagnostics
NASDAQ Capital Market
Adagio Medical Holdings
NASDAQ Capital Market
Adapthealth
NASDAQ Capital Market
Aethlon Medical
NASDAQ Capital Market
Agape ATP
NASDAQ Capital Market
FAQ
What is the BioAffinity Technologies share price?
As of Today at 19:35 UTC, shares in BioAffinity Technologies are trading at $0.45. This share price information is delayed by 15 minutes.
How has the BioAffinity Technologies share price performed this year?
Shares in BioAffinity Technologies last closed at $0.45 and the price had moved by -80.41% over the past 365 days. In terms of relative price strength the BioAffinity Technologies share price has underperformed the S&P500 Index by -82.34% over the past year.
What are the analyst and broker recommendations for BioAffinity Technologies?
The overall consensus recommendation for BioAffinity Technologies is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the BioAffinity Technologies dividend yield?
BioAffinity Technologies does not currently pay a dividend.
Does BioAffinity Technologies pay a dividend?
BioAffinity Technologies does not currently pay a dividend.
When does BioAffinity Technologies next pay dividends?
BioAffinity Technologies does not currently pay a dividend.
How do I buy BioAffinity Technologies shares?
To buy shares in BioAffinity Technologies you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of BioAffinity Technologies?
As of the previous close price of $0.45, shares in BioAffinity Technologies had a market capitalisation of $8.18m.
Where are BioAffinity Technologies shares listed?
Here are the trading details for BioAffinity Technologies:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: BIAF
What kind of share is BioAffinity Technologies?
Based on an overall assessment of its quality, value and momentum BioAffinity Technologies is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a BioAffinity Technologies share price forecast for 2025?
The analyst consensus target price for shares in BioAffinity Technologies is $6.00. That is 1237.79% above the last closing price of $0.45.
Analysts covering BioAffinity Technologies currently have a consensus Earnings Per Share (EPS) forecast of -$0.45 for the next financial year.
Find out moreWhat is the trend in the BioAffinity Technologies share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BioAffinity Technologies. Over the past six months, its share price has underperformed the S&P500 Index by -67.11%.
As of the last closing price of $0.45, shares in BioAffinity Technologies were trading -62.2% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the BioAffinity Technologies PE Ratio?
The BioAffinity Technologies PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.45.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of BioAffinity Technologies?
We do not have data on BioAffinity Technologies' directors